You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Epigenetic Pharmacotherapy for Addiction

    SBC: Epigenetix Inc            Topic: R41

    PROJECT SUMMARY This proposal aims to develop a new small molecule drug to be advanced into human clinical trials for the treatment of cocaine addiction According to the National Institute on Drug Abuse illicit drug use cost the United States more than $ billion annually in expenses related to crime lost work productivity and health care Approximately million Americans aged or older ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Device for Treatment of Congenital Diaphragmatic Hernia

    SBC: H-CUBED            Topic: NHLBI

    DESCRIPTION provided by applicant Congenital diaphragmatic hernia CDH affects in newborns CDH is a disorder in which part of the diaphragm fails to form allowing abdominal organs to migrate into the chest resulting in lung hypoplasia underdevelopment in affected infants Although great strides have been made in the management of this disease significant morbidity and mortality p ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. "Speed Bumps": A non-invasive quantitative test for early detection of neuropathy in the feet

    SBC: Neuro Devices, Inc.            Topic: 101

    ABSTRACT This STTR Phase I resubmission describes a small deceptively simple portable device called Speed Bumps that rapidly quantifies the sensation of flutter on the feet toes or fingers in micrometer m units Flutter frequency is to Hz which is below the approximate lower vibration range of to Hz This high sensitivity device is designed to differentiate the small variati ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Multi-Channel Transmit- Multi-Channel Receive Coil Array for Human fMRI

    SBC: LIFE SERVICES L.L.C.            Topic: 101

    DESCRIPTION provided by applicant For this Phase I STTR proposal the investigators plan to develop the radiofrequency RF coil technology required for high resolution fMRI at T In the absence of a body transmit coil all T head coils must also incorporate a transmitter in addition to the receiver Here we propose a transmit array with up to individual channels combined with a receive a ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Mobile Phone Intervention for Physical Activity Maintenance in African American Men (MobileMen)

    SBC: KLEIN BUENDEL, INC.            Topic: NIMHD

    DESCRIPTION provided by applicant African American men experience health disparities across a number of preventable chronic diseases including cardiovascular disease strokes obesity and diabetes Physical activity PA is a modifiable risk factor for these conditions The few PA promotion studies that have included African American men have resulted in successful short term behavior change ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Infectious Disease Diagnostics and Differentiation of Viral vs. Bacterial Infections for Point of Care Applications

    SBC: GENECAPTURE, INC.            Topic: CBD15C001

    The modern warfighter faces the constant threat of endemic infections, multi-drug resistant bacteria and Biological Warfare Agents. In order to provide accurate front-line treatment that will curtail the overuse of antibiotics, a rapid and robust molecula

    STTR Phase I 2016 Department of DefenseOffice for Chemical and Biological Defense
  7. Detecting Substandard, Nonconforming, Improperly Processed and Counterfeit Materiel

    SBC: VIBRANT CORP            Topic: DLA15C001

    Vibrant Corporation and Sandia National Laboratories (SNL) propose to apply Process Compensated Resonance Testing (PCRT) to the DLA's need for an NDI method to detect counterfeit, nonconforming and improperly processed materiel. PCRT collects and analyzes the resonance frequencies of a component to detect structural defects, characterize material, analyze population variation, monitor manufacturin ...

    STTR Phase I 2016 Department of DefenseDefense Logistics Agency
  8. OXAID: Oxygenating Hydrogel for Diabetic Wound Care

    SBC: O2 REGENTECH LLC            Topic: 200

    DESCRIPTION provided by applicant Oxygen plays a significant role in wound healing and maintaining elevated tissue oxygenation levels are an important factor in the dermal healing response Specifically non healing diabetic chronic wounds defined as lasting andgt weeks often show devastatingly low oxygen concentrations as low as mmHg oxygen partial pressure In the USA there are more ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Development of a novel platform to enhance intracellular bioavailability of antisense morpholino oligomers

    SBC: NAJIT TECHNOLOGIES, INC.            Topic: NIAID

    DESCRIPTION provided by applicant Peptide conjugated phosphorodiamidate morpholino oligomers PPMO are single stranded nucleic acid analogs able to modulate gene expression through steric blocking of complementary RNA PPMO are composed of two components an antisense morpholino oligomer cargo covalently conjugated to a cell penetrating delivery peptide PPMO are completely nuclease resistant ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Development of DRα1-MOG-35-55 for treatment of DR2 negative MS subjects

    SBC: VIROGENOMICS BIODEVELOPMENT, INC.            Topic: NIAID

    DESCRIPTION provided by applicant Our laboratory discovered and is developing partial p MHC class II constructs pMHC as a possible immunotherapy for multiple sclerosis MS pMHC containing the extracellular domains of the MS risk factor HLA DR linked covalently to the encephalitogenic peptide of myelin oligodendrocyte glycoprotein pDR MOG can reverse CNS inflammation and ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government